MarketCapExport financials
AnaptysBio (ANAB)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
AnaptysBio Balance Sheet 2026-2011 | ANAB
Brief overview of AnaptysBio's assets and capital
The balance sheet is assessed across five available annual reports spanning 2015 to 2019.
Assets rose from $56.3 million to $435.2 million, a gain of +673.3%, while CAGR was about 66.8%. The balance sheet expanded rapidly.
Liabilities increased less than assets, posting +116.5% versus +673.3%. That relationship usually strengthens the balance sheet.
Equity accounts for 93.1% of assets. Against the initial -62.5%, the capital position looks resilient.
The period ended with net cash: net debt stood at -$169.6 million. This supports financial flexibility.
The cash reserve occupies 39.3% of the balance sheet, previously 91.9%. It is one marker of short-term resilience.
Retained earnings are negative at -$244 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Balance sheet takeaway
The indicators point to a strong balance sheet position for AnaptysBio: funding is balanced and liability risks appear controlled.
Annual Balance Sheet AnaptysBio
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-121 M | -124 M | -7.04 M | -18.2 M | -51.9 M | -475 M | - | -170 M | -105 M | -66.8 M | -37.4 M | -46.8 M | -17.4 M | -1.99 M | - | - |
Long Term Debt |
10.9 M | 12 M | 14.1 M | 16 M | 17.8 M | 19.4 M | - | - | 625 K | 7.55 M | 13.8 M | 4.9 M | 4.79 M | - | - | - |
Long Term Debt Current |
2.16 M | 2.08 M | 1.92 M | 1.78 M | 1.64 M | 1.5 M | 342 K | 871 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | 654 K | 796 K | 7.69 M | 17.2 M | 6.57 M | 7.39 M | 607 K | - | - |
Total Current Liabilities |
35.4 M | 38.6 M | 45.4 M | 37.4 M | 26.1 M | 16.1 M | 19.8 M | 29.5 M | 21.8 M | 14.1 M | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | 30.2 M | 22.6 M | 21.8 M | 22.9 M | 13.9 M | 19.1 M | 3.77 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | 2.94 M | 10.1 M | 1.29 M | - | - |
Retained Earnings |
-642 M | -773 M | -759 M | -614 M | -450 M | -322 M | -264 M | -244 M | -147 M | -85 M | -54.9 M | -50.7 M | -45.3 M | -48.8 M | - | - |
Total Assets |
317 M | 364 M | 484 M | 452 M | 610 M | 643 M | 417 M | 435 M | 509 M | 329 M | 62.2 M | 56.3 M | 25.1 M | 3.91 M | - | - |
Cash and Cash Equivalents |
134 M | 138 M | 23.1 M | 36 M | 71.3 M | 496 M | 251 M | 171 M | 114 M | 81.2 M | 51.3 M | 51.7 M | - | - | - | - |
Book Value |
317 M | 364 M | 484 M | 452 M | 610 M | 643 M | 417 M | 405 M | 486 M | 308 M | 39.3 M | 42.3 M | 5.99 M | 145 K | - | - |
Total Shareholders Equity |
10.6 M | 37.2 M | 70.9 M | 88.1 M | 262 M | 356 M | 397 M | 405 M | 486 M | 308 M | -38.2 M | -35.2 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet AnaptysBio
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
11.5 M | 14.1 M | 12.6 M | 13.1 M | 13.6 M | 14.1 M | 14.6 M | 15.1 M | 15.6 M | 16 M | 16.5 M | 16.9 M | 17.4 M | 17.8 M | 18.2 M | 18.7 M | 19.1 M | 19.4 M | 19.8 M | 20.2 M | - | - | - | - | 419 K | 654 K | 654 K | 654 K | 654 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-825 M | -759 M | -822 M | -837 M | -799 M | -759 M | -738 M | -705 M | -658 M | -614 M | -572 M | -535 M | -495 M | -450 M | -424 M | -391 M | -358 M | -322 M | -289 M | -283 M | -282 M | -264 M | -264 M | -264 M | -264 M | -244 M | -244 M | -244 M | -244 M | -147 M | -147 M | -147 M | -147 M | -85 M | -85 M | -85 M | -85 M | -54.9 M | -54.9 M | -54.9 M | -54.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
330 M | 484 M | 353 M | 335 M | 422 M | 484 M | 493 M | 427 M | 406 M | 452 M | 487 M | 517 M | 552 M | 610 M | 619 M | 604 M | 625 M | 643 M | 424 M | 427 M | 396 M | 417 M | 417 M | 417 M | 417 M | 435 M | 435 M | 435 M | 435 M | 509 M | 509 M | 509 M | 509 M | 329 M | 329 M | 329 M | 329 M | 62.2 M | 62.2 M | 62.2 M | 62.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
248 M | 71.3 M | 110 M | 44.3 M | 98.6 M | 123 M | 192 M | 71.8 M | 53.7 M | 36 M | 26.3 M | 35.2 M | 94.6 M | 71.3 M | 58.5 M | 71.7 M | 166 M | 496 M | 336 M | 332 M | 284 M | 251 M | 250 M | 250 M | 250 M | 171 M | 171 M | 171 M | 171 M | 114 M | 114 M | 114 M | 114 M | 81.2 M | 81.2 M | 81.2 M | 81.2 M | 51.2 M | 51.2 M | 51.2 M | 51.2 M | 51.7 M | - | - | - | 22.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
330 M | 484 M | 353 M | 335 M | 422 M | 484 M | 493 M | 427 M | 406 M | 452 M | 487 M | 517 M | 552 M | 610 M | 619 M | 604 M | 625 M | 643 M | 424 M | 427 M | 396 M | 417 M | 417 M | 417 M | 417 M | 435 M | 435 M | 435 M | 435 M | 509 M | 509 M | 509 M | 509 M | 329 M | 329 M | 329 M | 329 M | 62.2 M | 62.2 M | 62.2 M | 62.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
12.7 M | 262 M | -29.4 M | -44.7 M | 34 M | 70.9 M | 84.4 M | 9.88 M | 47.8 M | 88.1 M | 120 M | 148 M | 191 M | 262 M | 278 M | 304 M | 331 M | 356 M | 384 M | 386 M | 382 M | 397 M | 397 M | 397 M | 397 M | 405 M | 405 M | 405 M | 405 M | 486 M | 486 M | 486 M | 486 M | 308 M | 308 M | 308 M | 308 M | -38.2 M | -38.2 M | -38.2 M | -38.2 M | -35.2 M | - | - | - | -30.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of AnaptysBio, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
